Epithelial ovarian cancer represents the nineth highest in cancer incidence and the fifth highest in site-specific causes of cancer deaths in women in the Western countries ([@bib33]). Only 25--30% of all cases are diagnosed with an early stage, good prognosis disease (Federation of Gynaecology and Obstetrics (FIGO) stage I--IIA; 5-year overall survival (OS)=90--95%) as most patients are still diagnosed with an advanced stage, with a 5-year OS of 30--50% ([@bib17]; [@bib35]).

The optimal treatment is currently based on cytoreductive surgery and adjuvant platinum-based chemotherapy. In early stage cancer the primary surgery includes hysterectomy, bilateral salpingo-oophorectomy, infracolic or infragastric omentectomy and peritoneal biopsies, whereas in case of advanced disease the goal is the complete cytoreduction of all visible tumour ([@bib6]; [@bib34]; [@bib35]).

The role of lymphadenectomy as a part of the surgical treatment of ovarian cancer has been debated over the last 30 years Retroperitoneal lymph node involvement occurs in ∼5--25% and 50--80% of women with early and advanced ovarian cancer, respectively. Retrospective studies have suggested that removal of the lymph nodes is associated with an improvement of staging and a survival benefit ([@bib11]; [@bib13]; [@bib8]; [@bib4]; [@bib19]; [@bib20]; [@bib31]; [@bib32]; [@bib14]).

In Italy, in 1990, comprehensive programs, coordinated at the Mario Negri Institute (Milan), were designed to evaluate, by randomised clinical trials (RCT), the impact of lymphadenectomy in ovarian carcinoma. Such programme aimed at evaluating staging accuracy and survival in macroscopic disease confined to the pelvis [@bib21] or in optimally debulked (previously defined as \<1 cm) advanced stage ([@bib5]).

This trial,was launched to assess the influence of lymphadenectomy, performed at second look after primary surgery and adjuvant chemotherapy, on the survival rates of women with stage IA--IV ovarian cancer.

Patients and methods
====================

Patient eligibility
-------------------

Patients with histologically proven epithelial ovarian carcinoma with FIGO stages IA-IV ([@bib15]), after primary surgery, with or without adjuvant chemotherapy and no evidence of disease on chest, abdominal and pelvic computed tomography scan, were eligible for participation in the study.

Additional eligibility criteria included age of \>75 years, the Karnofsky performance status of ⩾80. Patients who underwent retroperitoneal evaluation at first surgery or had second-look surgery \>12 months after first surgery were not eligible. The study protocol was revised and accepted by Local Ethics Committees, and appropriate written informed consent was obtained from all patients.

Randomisation procedures
------------------------

Random assignment of patients, who had an equal probability of assignment to either treatment arm, was carried out by a block arrangement that balances the treatment assignment within each site. Randomisation was performed centrally by telephone at the Mario Negri Institute, Milan.

Patients were randomly assigned intra-operatively after open laparotomy when the surgeon was sure that the tumour was properly debulked (residual tumour \<1 cm).

Data from all eligible patients were analysed for survival on an intention-to-treat basis.

Patient characteristics
-----------------------

Pretreatment clinical and tumour characteristics, operative details of primary surgery, front-line chemotherapy and operative details of second look surgical procedures were collected soon after surgery.

Chemotherapy and initial follow-up data were collected 6 months after surgery, and further follow-up data were collected annually thereafter. Data were sent to the Mario Negri Institute, Milan.

Surgical procedures
-------------------

### Control arm

An attempt to achieve an optimal cytoreduction for any metastatic peritoneal implants was carried on, followed by the resection of all suspicious lymph nodes of ⩾1 cm in diameter.

### Systematic lymphadenectomy arm

Secondary cytoreductive surgery as detailed for the control arm was followed by systematic pelvic and aortic lymphadenectomy.

Pelvic lymphadenectomy included external and internal iliac, superficial and deep common iliac, superficial and deep obturator and presacral nodes Unilateral lymphadenectomy was allowed in unilateral tumours. Bilateral pelvic lymph node dissection was deemed satisfactory when at least 25 nodes were removed (12 in case of unilateral lymphadenectomy).

Aortic lymphadenectomy dissection began at the aortic bifurcation up to the renal vessels by removing superficial and deep intercavoaortic, precaval, paracaval and retrocaval, preaortic and paraaortic nodes aortic lymphadenectomy was considered appropriate when at least 15 nodes were removed. In case of previous diagnosis of unilateral right ovarian cancer stage IA--IIA the dissection of the paraaortic nodes was optional. Similarly, in case of previous diagnosis of unilateral left ovarian cancer stage IA--IIA the dissection of the paracaval nodes was optional In these cases, the aortic lymphadenectomy was considered appropriate when at least 10 nodes were removed.

Second-line chemotherapy
------------------------

All patients, regardless of the trial arm, were recommended to undergo a second-line chemotherapy in case of microscopic positive histological findings (i.e., biopsies or cytology), in case of macroscopic tumour surgically converted to a complete cytoreduction or in case of any residual tumour at the second-look surgery. A 'consolidation\' chemotherapy was optional in case of negative histology.

Patients found to have progressive disease on follow-up were provided with further treatment at the discretion of the treating physician.

Statistical analysis
--------------------

The primary endpoint of this study was OS, defined as the time from randomisation to death from any cause.

Secondary endpoints included surgical morbidity and progression-free survival (PFS), defined as the time from randomisation to the earliest occurrence of progression or death from any cause.

In pre-trial analysis, we calculated that when a type I error is limited to.05 (two-tailed test), a total of about 300 patients would need to be accrued to afford an 80% power to detect a 36% relative reduction in the mortality hazard rate of patients in the systematic lymphadenectomy (i.e., increasing the 5-year survival rate from 64 to 75%, which corresponds to a hazard ratio (HR) of 0.64).

Survival curves were estimated by the Kaplan--Meier method ([@bib18]) and compared using the log-rank test ([@bib25]).

Additional analyses were performed with the Cox proportional hazards model adjusting for multiple baseline characteristics. Proportional hazards assumptions were checked by plotting log{−log \[S(*t*)\]} against log *t* for each group and found to be satisfied ([@bib24]).

Comparison of proportions between groups was performed using a two-sided *χ*^2^ test or, if the number of patients in a given category was less than five, a two-sided Fisher\'s exact test. Continuous data, including number of resected nodes, operating time, blood loss and hospital stay, were expressed as medians with interquartile ranges and were compared using a two-sided Kruskal--Wallis (nonparametric) test.

Results
=======

Patient accrual
---------------

Between January 1991 and May 2001, 322 patients were enroled in the study at six centres. After pathological and clinical review, 14 patients were deemed ineligible. [Figure 1](#fig1){ref-type="fig"} shows the trial flow diagram and details reasons for patient ineligibility.

Patient characteristics
-----------------------

The clinical and tumour characteristics of eligible patients are listed in [Table 1](#tbl1){ref-type="table"}. Characteristics appear to be well balanced across treatment arms.

Approximately 50% of patients had residual disease \>1 cm after primary surgery and the vast majority of patients received chemotherapy after primary cytoreductive surgery, 140 in the biopsy arm and 147 in the lymphadenectomy arm (93% in each arm). In total, 21 women did not undergo chemotherapy, of which 16 out of 70 women with early stage IA--IIA (8 in each arms) and 5 out of 238 women with advanced stage IIB--IV (2 *vs* 3 in the two arms).

No differences in chemotherapy schedules were found between the two trial arms (*P*=0.42); 98% of patients underwent platinum-based chemotherapy regimens, and only 2% of patients received non-platinum-based chemotherapy regimens. In particular, a platinum mono-chemotherapy was used in 108 women (47 assigned to lymphadenectomy *vs* 61 assigned to no-lymphadenectomy) a platinum--taxanes in 31 (14 *vs* 17) and platinum+others in 142 (76 *vs* 66) patients, respectively.

The median number of cycles administered was 6 (range 2--10).

At the end of second-look surgery 18 patients (6%) had residual disease, all \<1 cm.

Surgical procedures
-------------------

The surgical procedures performed during second-look surgery before the randomisation are listed in [Table 2](#tbl2){ref-type="table"}.

[Table 3](#tbl3){ref-type="table"} shows the median number and inter-quartile range of resected nodes by treatment arm. In the systematic lymphadenectomy arm, the median number of removed pelvic and aortic lymph nodes was 23 (interquartile range=15--33) and 20 (interquartile range=13--28), respectively. Overall, the median number of removed nodes was 44 (interquartile range=30--63) in the lymphadenectomy arm and 8 (interquartile range=4--14.5) in the control arm. At least one positive pelvic or aortic node was detected in 58 women (18.8%), 38 in the lymphadenectomy arm and 20 in the non-lymphadenectomy arm (24.2% *vs* 13.3%, *P*=0.02).

In particular, in the group of women with stage IA--IIA disease, nodal metastases were found in 3/30 women in the lymphadenectomy arm *vs* 2/40 women in the non-lymphadenectomy arm. In the subgroup of women with stage IIB--IV disease, 35/128 women in the lymphadenectomy arm *vs* 18/110 women in the non-lymphadenectomy arm had nodal metastases.

In the patients assigned to lymphadenectomy arm, nodal metastases were found in 8/59 (13.6%) women with no evidence of residual tumour *vs* in 30/99 (30.3%) women who had any residual tumour at the end of primary surgery (*P*=0.165).

Furthermore, nodal metastases were depicted in the lymphadenectomy arm, in 26/123 (21.1%) and 12/34 (35.3%), in women with no evidence of peritoneal tumour *vs* the presence of any tumour at the beginning of the second-look surgery (*P*=0.088).

Systematic lymphadenectomy had a statistically significant impact on surgical parameters such as median operative time, blood loss, blood transfusions and the number of hospital days ([Table 4](#tbl4){ref-type="table"}).

Although the number of intra-operative complications was similar between the two arms (i.e., two in the control arm and seven in lymphadenectomy arm, *P*=0.106), systematic lymphadenectomy had greater perioperative and late morbidity (14 patients *vs* 3 patients in the control arm, *P*=0.008). Most of the difference in morbidity between the two trial arms was due to the formation of lymphocysts and lymphedema that occurred in six patients in the systematic lymphadenectomy group *vs* no patients in the control arm. The frequency of remaining postoperative complications were as follows: radicular damage (2 *vs* 0 patients), intestinal fistula (1 *vs* 0 patients), hemoperitoneum (1 *vs* 0 patients), fever (2 *vs* 1 patients), surgical wound diastasis (0 *vs* 2 patients) and adhesive small bowel obstruction (2 *vs* 0 patient). No surgery-related deaths occurred.

Second-line chemotherapy after second-look surgery
--------------------------------------------------

Overall, 138 (45%) out 308 patients received chemotherapy after second-look surgery (43% in the control arm and 47% in the systematic lymphadenectomy arm; *P*=0.46). In total, 79% of patients with macroscopic evidence of tumour at the beginning of second-look surgery or positive nodes underwent chemotherapy treatment whereas 28% of patients without evidence of the disease at second look and negative nodes underwent consolidation chemotherapy. No differences in chemotherapy schedules were found between the two trial arms with 70% of patients undergoing platinum or platinum-based chemotherapy regimens.

Progression-free and OS
-----------------------

At a median follow-up of 111 months (25--75th percentiles: 88--148 months) tumour has recurred in 163 patients (52.9%) and 124 patients (40.3%) have so far died. Recurrence was experienced by 74 patients (49.3%) in the control arm and by 89 patients (56.3%) who underwent systematic lymphadenectomy. The pattern of disease recurrences, stratified by stage of disease, are listed in [Table 5](#tbl5){ref-type="table"}.

[Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"} depict the overall and PFS, respectively, for all eligible patients.

Median PFS was 68.7 months. At 3--5--10 years, 58.8% *vs* 50.5%, 53.8% *vs* 40.9% and 44.4% *vs* 39.4% of women in the control arm and in the lymphadenectomy arm, respectively, did not relapse. The HR for relapse in the group assigned to lymphadenectomy as compared with the group assigned to control was 1.18 (95% confidence interval (CI)=0.87--1.59; *P*=0.29).

Median OS was not reached at the time of analysis. At 3--5--10 years, 77.7% *vs* 79.6%, 67.4% *vs* 63.5% and 56.2% *vs* 54.2% of women in the control arm and in the lymphadenectomy arm, respectively, were alive. The HR for death in the group assigned to lymphadenectomy as compared with the group assigned to control was 1.04 (95% CI=0.733--1.49; *P*=0.81).

A Cox proportional hazards analysis was performed to adjust the treatment comparison for baseline characteristics. When stage was taken into account the new HRs for death and progression remained virtually unchanged ([Table 6](#tbl6){ref-type="table"}).

A subgroup analysis in women with stage IA--IIA and stage IIB--IV disease was performed to evaluate the impact of lymphadenectomy in the different subsets of women. In the early stage subgroup the HR for relapse was 1.3 (95% CI=0.46--3.77; *P*=0.60) and HR for death was 1.26 (95% CI=0.41--3.91; *P*=0.69). In advanced stage the HR for relapse was 1.06 (95% CI=0.77--1.45; *P*=0.73) and for death was 0.96 (95% CI=0.66--1.40; *P*=0.83).

We performed also a separate survival analyses also in women with no residual tumour *vs* women with any residual disease at the end of primary surgery. Among women completely debulked the HR for relapse was 1.60 (95% CI=0.86--2.97; *P*=0.14) and for death was 1.75 (95% CI=0.86--3.57; *P*=0.12), whereas in women not completely debulked the HR for relapse was 1.60 (95% CI=0.86--2.97; *P*=0.14) and for death was 0.81 (95% CI=0.53--1.23; *P*=0.32).

Discussion
==========

Second-look surgery for ovarian cancer was introduced in the clinical practice with the main objective of accurately assessing the pathological findings in the peritoneal cavity and in pelvic and aortic nodes areas in women with apparent complete response to the front-line chemotherapy. The philosophy of second-look surgery is based on the belief that an early identification of micro- or macroscopic-resistant disease to the first-line chemotherapy, the debulking of such resistant tumour and the immediate consolidation or the second-line chemotherapy could increase the OS. A secondary objective of the second-look surgery was the restaging of women who underwent primary inadequate surgery and to complete the endo- or retro-peritoneal cytoreduction if macroscopic disease is encountered ([@bib27]).

The most important clinical variable influencing the presence of tumour at second-look surgery is stage. Residual tumour at second look has been described in 5--15% of women with early stage cancer, according to the adequateness of surgical staging at primary surgery. Conversely, in advanced stage, a positive histology at second look has been described in almost 25% in women with no residual disease and 50--70% in women with bulky residual tumours ([@bib29]; [@bib3]; [@bib26]; [@bib10]; [@bib1]).

The literature regarding second-look surgery is rife with conflicting data. Although some authors reported a survival advantage for women undergoing second-look surgery who were completed and/or optimally debulked as compared with women not optimally debulked, others authors did not confirm these results. Second-look surgery was performed particularly during the 1980s and 1990s but over the last 10 years it has been abandoned from the vast majority of the gynaecological oncology centres as clinicians progressively recognised that up to 50% of women with proved pathological complete response to chemotherapy still face recurrent disease, with a median time to recurrence ranging between 14 and 24 months ([@bib16]; [@bib12]; [@bib30]; [@bib27]; [@bib23]). [@bib22] showed by a small RCT that although the second-look surgery in advanced stage ovarian cancer accurately defined the complete responders it failed to demonstrated a survival benefit.

When we launched this RCT, the second-look surgery was widely performed in Italian gynaecological cancer centres and we decided to investigate by a RCT if lymphadenectomy would improve survival in women with apparent complete clinical response to primary surgery and front-line chemotherapy who underwent second-look surgery and to verify the possible different peritoneal *vs* nodal response to the chemotherapy.

Lymphadenectomy at the second look is aimed at removing small nodal metastases not otherwise detectable by clinical evaluation or palpation or by preoperative imaging. The potential benefit of this is the removal of resistant clones of tumour cells or of a poorly vascularised tumour (pharmacologic sanctuaries), which in turn, should decrease the likelihood of the early onset of drug resistance ([@bib13]; [@bib7]; [@bib31]; [@bib14]). Apart from the potential survival advantage, the resection of lymph nodes at second-look surgery can avoid isolated lymph node recurrences that lead to a subsequent cytotoxic treatment or further nodal cytoreductive surgery followed by chemotherapy thus increasing morbidity and costs.

Only scanty data are available on the value of lymphadenectomy at second-look surgery ([@bib36]; [@bib9]). [@bib2] published a small cohort of 58 women, stage I--IV, with apparent complete response to chemotherapy, undergoing systematic lymphadenectomy between 1974 and 1993. In total, 15 out of 58 women (26%) had nodal metastases. In particular, nodal metastases were found in 22% and 33% of women with early and advanced stage disease, respectively, and in 17.7% of women with no evidence of intraperitoneal disease compared with 64% of women with peritoneal residual disease at the second look. The only factors influencing the risk of relapse were the advanced stage, the grade 3 and the presence of residual disease at the primary surgery while no relation emerged between the relapse and the nodal status at the second look (relapse rate 27% *vs* 25%). The rate of nodal metastases (17.7%) at the second look in this retrospective study is consistent with the data from [@bib28] who reported an exclusively nodal relapse in 20% of women with a pathological proved complete response.

The role of systematic lymphadenectomy, in the treatment of ovarian cancer, has been evaluated in three RCTs over 10 years. Systematic pelvic and aortic lymphadenectomy improved only staging in women with cancer confined to the pelvis and PFS in the advanced stage ovarian cancer, but it failed to demonstrate a survival benefit in either group ([@bib5]; [@bib21]).

The current RCT found that the systematic lymphadenectomy, compared with simple nodal biopsy, enabled to detect a higher number of patients with metastatic lymph nodes (24.2% *vs* 13.3%). This study also showed that systematic lymphadenectomy is a relatively safe surgical procedure, if provided by trained gynaecology oncologists. Notwithstanding, systematic lymphadenectomy is associated with an increased operating time, blood loss, blood transfusions, hospital stay and a higher incidence of postoperative complications, consisting mainly of lymphocysts or lymphedema. Such data are in keeping with the results of the other two randomised studies in early or advanced ovarian cancer.

This trial was designed to assess OS as primary endpoint and PFS as secondary endpoint. We found that patients who underwent systemic lymphadenectomy had neither OS nor disease-free survival benefits when compared with patients who underwent removal of bulky nodes only. Furthermore, no difference in the pattern of relapse was found and also the number of nodal relapses was the same between the two groups ([Table 5](#tbl5){ref-type="table"}).

The stage of the disease at the moment of the diagnosis had a strong influence on the prevalence of nodal involvement at second look. When looking at patients enroled in the lymphadenectomy arm, only 10% of women staged IA-IIA had nodal metastases (4.5% in the 22 patients who underwent adjuvant chemotherapy) but this proportion increased to 27.2% in patients with more advanced disease at first diagnosis. These findings show that chemotherapy, although active, is not able to eradicate all cancer foci in lymph nodes, especially in advanced disease. Otherwise, markers of disease aggressiveness, namely residual tumour at the end of primary surgery and the presence of peritoneal macroscopic tumour at second-look surgery were strong predictor of nodal involvement. In fact, in the lymphadenectomy arm, the prevalence of nodal metastases was statistically correlated with the residual tumour at the primary surgery (13.6% in patients with no residual tumour *vs* 30.3% in patients with residual tumour, *P*=0.165), as well as with an evidence of peritoneal spread at the time of second look (21.1% absent *vs* 35.3% present, *P*=0.088). Notably, both arms showed similar proportion of patients undergoing second-line chemotherapy, notwistanding wide difference in nodal involvement detection, and this allowed to explore the pure surgical debulking impact of lymphadenectomy on survival.

The limitations of our study must be ackwoledged. First, the trial took a long time to recruit and mature. Although many technological and scientific changes have occurred over such a long time the platinum-based chemotherapy regimens were widely used in this selected population and, above all, the randomisation procedure should have avoided the introduction of any systematic bias between arms. Another potential study limitation relates to the fact that second-look surgery, as performed in this trial, often tried to compensate first surgery inadequacy as shown in [Table 2](#tbl2){ref-type="table"} where types of second look surgical procedures were described. The inappropriateness of first surgery, according to modern standards, was due to the fact that most of the patients were randomised in specialised clinics where patients were addressed after just diagnostic explorative surgery undergone in minor general hospitals.

Overall, our data showed a lack of benefit in overall and PFS in patients who underwent lymphadenectomy at second look. Subgroup analyses in early and advanced disease failed to show survival benefit as well. These results should discourage the use of routine lymphadenectomy at second-look surgery after first-line chemotherapy in women with ovarian cancer. Furthermore, among the 238 women with advanced stage disease, of which 220 women with no residual tumour at the end of second-look surgery (absent or surgical converted to absent), lymphadenectomy was not associated with a survival gain (HR for relapse: 1.06; 95% CI=0.77--1.45; *P*=0.73 and HR for death: 0.96; 95% CI=0.66--1.40; *P*=0.83). Currently, the lymphadenectomy in ovarian neoplasm international RCT, sponsored by the onco-gynaecologic German group AGO, that investigates the role of systematic lymphadenectomy at primary surgery in advanced stage IIB--IV ovarian cancer, completed debulked, has enroled almost 650 women and the results are awaited.

In conclusion, according to this RCT a systematic lymphadenectomy at the second-look surgery after first-line chemotherapy in women with ovarian cancer offers no benefit. When a second-look surgery is required, because of an incomplete/inadequate endoperitoneal cytoreductive primary surgery, only nodal biopsies or removal of suspicious nodes should be performed, both in early and in advanced stage.
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###### Patients characteristics

                                          **No lymphadenectomy (*****N*****=150)**  **Lymphadenectomy (*****N*****=158)**         
  -------------------------------------- ------------------------------------------ --------------------------------------- ----- ------
  Median age (25--75th percentiles)                     52 (45--60)                 50 (44--58)                                   
                                                                                                                                  
  *FIGO stage (primary surgery)*                                                                                                  
   I                                                         36                     24.0                                     26   16.5
    IA                                                       8                                                                6    
    IB                                                       5                                                                1    
    IC                                                       23                                                              19    
   II                                                        17                     11.5                                     25   15.8
    IIA                                                      4                                                                4    
    IIB                                                      7                                                               14    
    IIC                                                      6                                                                7    
   III                                                       90                     60.0                                     99   62.6
    IIIA                                                     3                                                                7    
    IIIB                                                     11                                                               7    
    IIIC                                                     76                                                              85    
   IV                                                        6                      4.0                                       8   5.1
    Missing data                                             1                      1.5                                       0   0
                                                                                                                                  
  *Residual tumour at first surgery*                                                                                              
    Absent                                                   57                     38.0                                     59   37.3
    ⩽1 cm                                                    8                      5.3                                      21   13.3
    \>1 cm                                                   73                     48.7                                     72   45.6
    Missing data                                             12                     8.0                                       6   3.8
                                                                                                                                  
  *Tumour grade*                                                                                                                  
    One well differentiated                                  17                     11.3                                     12   7.6
    Two moderately well differentiated                       36                     24.0                                     35   22.2
    Three poorly differentiated                              87                     58.0                                     105  66.5
    Missing data                                             10                     6.7                                       6   3.8
                                                                                                                                  
  *Cell type*                                                                                                                     
    Serous                                                   79                     52.7                                     100  63.3
    Endometriod                                              31                     20.7                                     15   9.5
    Mucinous                                                 8                      5.3                                       7   4.4
    Clear-cell                                               8                      5.3                                      13   8.2
    Undifferentiated                                         8                      5.3                                      15   9.5
    Other                                                    8                      5.3                                       6   3.8
    Missing data                                             8                      5.3                                       2   1.3
                                                                                                                                  
  *Residual tumour at II look surgery*                                                                                            
    Absent                                                  118                     78.7                                     123  77.8
    Surgically converted to absent                           22                     14.7                                     26   16.4
    ⩽1 cm                                                    10                     6.7                                       8   5.1
    Missing data                                             0                      0                                         1   0.6

Abbreviation: FIGO=Federation of Gynaecology and Obstetrics.

###### surgical procedures at the II look surgery

  **Surgical procedures**              **No lymphadenectomy (*****N*****=150)**   **Lymphadenectomy (*****N*****=158)**  **Total (*****N*****=308) (%)**
  ----------------------------------- ------------------------------------------ --------------------------------------- ---------------------------------
  *Hysterectomy*                                      55 (36.9%)                               59 (37.8%)                114 (37.4)
   Missing data                                           1                                         2                    3 (0.9)
  *Unilateral or bilateral*                            42 (28%)                                 38 (24%)                 80 (26)
  *salpingo-oophorectomy*                             14 and 28                                 13 and 25                27 and 53
   Missing data                                           1                                         1                    2 (0.6)
  *Omentectomy*                                      107 (71.3%)                                101 (64%)                208 (67.5)
   Missing data                                           1                                         1                    2 (0.6)
  *Appendectomy*                                      36 (24.2%)                               45 (28.7%)                81 (26.5)
   Missing data                                           1                                         1                    2 (0.6)
  *Small bowel resection*                              1 (0.7%)                                     0                    1 (0.3)
   Missing data                                           1                                         1                    2 (0.6)
  *Rectosigmoid or colon resection*                     6 (4%)                                  1 (0.6%)                 7 (2.3)
   Missing data                                           1                                         1                    2 (0.6)
  *Pelvic peritonectomy*                               8 (5.4%)                                 8 (5.1%)                 16 (5.2)
   Missing data                                           1                                         1                    2 (0.6)
  *Diaphragm stripping/resection*                      4 (2.7%)                                 1 (0.6%)                 5 (1.6)
   Missing data                                           1                                         1                    2 (0.6)

###### Median number (25--75th percentiles) of resected nodes by treatment arm

  **Nodal site**            **No lymphadenectomy (*****N*****=150)**   **Lymphadenectomy (*****N*****=158)**   ***P***
  ------------------------- ------------------------------------------ --------------------------------------- ---------
  Pelvic                    5 (1.5--10)                                23 (15--33)                             \<0.001
  Lumbo-aortic              2 (0--4)                                   20 (13--28)                             \<0.001
  Pelvic and lumbo-aortic   8 (4--14.5)                                44 (30--63)                             \<0.001
  Missing data              6                                          1                                        

###### Operative details and postoperative hospital stay

  **Operative details**           **No lymphadenectomy (*****N*****=150)**   **Lymphadenectomy (*****N*****=158)**   ***P***
  ------------------------------- ------------------------------------------ --------------------------------------- ---------
  *Median operating time (min)*   135                                        230                                     \<0.001
   (25--75th percentiles)         (100--180)                                 (180--270)                               
   Missing data                   7                                          13                                       
  *Median blood loss (ml)*        200                                        400                                     \<0.001
   (25--75th percentiles)         (150--350)                                 (300--700)                               
   Missing data                   17                                         21                                       
  *Patients transfused (%)*       14 (9.3%)                                  46 (29.1%)                              \<0.001
   Missing data                   0                                          0                                        
  *Median hospital stay (days)*   6                                          7                                       0.0015
   (25--75th percentiles)         (5--8)                                     (6--8)                                   
   Missing data                   11                                         20                                       

###### Site of disease recurrence by stage and treatment arm

                    **No lymphadenectomy (*****N*****=150)**   **Lymphadenectomy (*****N*****=158)**   **Total**                          
  ----------------- ------------------------------------------ --------------------------------------- ------------ --- ---- ------------ -----
  Pelvic            2                                          13                                      15 (10%)     2   33   35 (22.2%)   50
  Intraperitoneal   0                                          10                                      10 (6.7%)    2   15   17 (10.8%)   27
  Lymphnode         0                                          4                                       4 (2.7%)     1   4    5 (3.2%)     9
  Distant site      2                                          9                                       11 (7.3%)    0   9    9 (5.7%)     20
  Multiple sites    2                                          26                                      28 (18.7%)   0   16   16 (10.1%)   44
  Missing data                                                                                         6 (4%)                7 (4.4%)     13
  Total             6                                          62                                      74 (49.3%)   5   77   89 (56.3%)   163

###### Multivariable Cox proportional hazards analysis for PFS and OS to adjust the risk associated with therapy for various prognostic factors[a](#t6-fn2){ref-type="fn"}

                                                         **PFS**        **OS**                       
  ------------------------------------------------ ------------------- --------- ------------------- ---------
  *Treatment arm*                                                                                    
   No lymphadenectomy[b](#t6-fn3){ref-type="fn"}            1            0.50             1            0.97
   Lymphadenectomy                                  1.11 (0.82--1.50)             1.00 (0.71--1.44)       
                                                                                                     
  *FIGO stage at primary surgery*                                                                    
   1 or 2[b](#t6-fn3){ref-type="fn"}                        1           \<0.001           1           \<0.001
   3 or 4                                           2.90 (1.98--4.24)             3.26 (2.02--5.27)       

Abbreviations: FIGO=Federation of Gynaecology and Obstetrics; HR=hazard ratio; OS=overall survival; PFS=progression-free survival; 95% CI=confidence interval.

HR; 95% CI.
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